Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.On September 24, 2024, Ross Segan was appointed to replace Maisel as the head of medical device evaluation and quality at the FDA's Center for Devices and Radiological Health. Route 92 Medical raised $50 million in funding to support global sales of stroke devices, with a total of $82 million raised so far. A study found that recalled heart devices had limited clinical testing, with only 30 out of 157 devices undergoing premarket clinical testing. Stryker acquired Nico, adding devices for removing brain tumors and clots to their portfolio. Legacy medical devices with unsupported software pose cybersecurity threats, and experts recommend four steps to minimize these risks.Epic, a major electronic health record vendor, is being sued for alleged antitrust violations by data startup Particle Health. Senator Ron Wyden is pressuring hospitals on EMTALA compliance after reports of women being denied emergency abortions. Supply chain cyberattacks are threatening the healthcare industry, prompting the need for collaborative efforts to limit disruption. The use of artificial intelligence in healthcare is a complex issue that involves balancing innovation, efficiency, accuracy, bias, and ethics.Biogen and UCB have achieved positive lupus data after waiting for two decades, prompting them to start a large study on their medicine, dapirolizumab pegol. Bluebird is restructuring again, laying off 25% of its workforce to preserve cash amid slow uptake of its gene therapies. Metsera is promoting a long-acting GLP-1 drug for weight loss, while Novartis has struck an AI deal. Biohaven plans to seek FDA approval for a neurological disorder drug after positive data. The biopharma industry is seeing developments in long-acting obesity drugs, AI deals, and restructuring efforts to manage financial challenges.The text discusses the importance of data in cancer research and how the nonprofit Cancer Research Institute, led by Alicia Zhou, is leveraging data to pursue treatments and cures. Zhou aims to foster collaboration between industry and government sectors to improve cancer drug development. The text also highlights the importance of making biopharma more like Silicon Valley to address cancer research challenges from a multi-faceted perspective.